Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling - PubMed (original) (raw)
. 2004 Jul 30;279(31):32269-74.
doi: 10.1074/jbc.M404789200. Epub 2004 May 27.
Affiliations
- PMID: 15166220
- DOI: 10.1074/jbc.M404789200
Free article
Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling
Laure Dumoutier et al. J Biol Chem. 2004.
Free article
Abstract
Interferon (IFN)-lambda 1, -lambda 2, and -lambda 3 are the latest members of the class II cytokine family and were shown to have antiviral activity. Their receptor is composed of two chains, interleukin-28R/likely interleukin or cytokine or receptor 2 (IL-28R/LICR2) and IL-10R beta, and mediates the tyrosine phosphorylation of STAT1, STAT2, STAT3, and STAT5. Here, we show that activation of this receptor by IFN-lambda 1 can also inhibit cell proliferation and induce STAT4 phosphorylation, further extending functional similarities with type I IFNs. We used IL-28R/LICR2-mutated receptors to identify the tyrosines required for STAT activation, as well as antiproliferative and antiviral activities. We found that IFN-lambda 1-induced STAT2 tyrosine phosphorylation is mediated through tyrosines 343 and 517 of the receptor, which showed some similarities with tyrosines from type I IFN receptors involved in STAT2 activation. These two tyrosines were also responsible for antiviral and antiproliferative activities of IFN-lambda 1. By contrast, STAT4 phosphorylation (and to some extent STAT3 activation) was independent from IL-28R/LICR2 tyrosine residues. Taken together, these observations extend the functional similarities between IFN-lambdas and type I IFNs and shed some new light on the mechanisms of activation of STAT2 and STAT4 by these cytokines.
Similar articles
- Identification of a novel conserved motif in the STAT family that is required for tyrosine phosphorylation.
Gamero AM, Sakamoto S, Montenegro J, Larner AC. Gamero AM, et al. J Biol Chem. 2004 Mar 26;279(13):12379-85. doi: 10.1074/jbc.M310787200. Epub 2004 Jan 13. J Biol Chem. 2004. PMID: 14722125 - The proximal tyrosines of the cytoplasmic domain of the beta chain of the type I interferon receptor are essential for signal transducer and activator of transcription (Stat) 2 activation. Evidence that two Stat2 sites are required to reach a threshold of interferon alpha-induced Stat2 tyrosine phosphorylation that allows normal formation of interferon-stimulated gene factor 3.
Nadeau OW, Domanski P, Usacheva A, Uddin S, Platanias LC, Pitha P, Raz R, Levy D, Majchrzak B, Fish E, Colamonici OR. Nadeau OW, et al. J Biol Chem. 1999 Feb 12;274(7):4045-52. doi: 10.1074/jbc.274.7.4045. J Biol Chem. 1999. PMID: 9933596 - Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C.
Radaeva S, Jaruga B, Kim WH, Heller T, Liang TJ, Gao B. Radaeva S, et al. Biochem J. 2004 Apr 1;379(Pt 1):199-208. doi: 10.1042/BJ20031495. Biochem J. 2004. PMID: 14690454 Free PMC article. - STAT proteins: signal tranducers and activators of transcription.
Bromberg J, Chen X. Bromberg J, et al. Methods Enzymol. 2001;333:138-51. doi: 10.1016/s0076-6879(01)33052-5. Methods Enzymol. 2001. PMID: 11400331 Review. No abstract available. - IL-28 and IL-29: newcomers to the interferon family.
Uzé G, Monneron D. Uzé G, et al. Biochimie. 2007 Jun-Jul;89(6-7):729-34. doi: 10.1016/j.biochi.2007.01.008. Epub 2007 Jan 27. Biochimie. 2007. PMID: 17367910 Review.
Cited by
- Association analysis between SNPs in IL-28B gene and the progress of hepatitis B infection in Han Chinese.
Chen J, Wang L, Li Y, Cai B, Fu Y, Liao Y, Zhang J. Chen J, et al. PLoS One. 2012;7(12):e50787. doi: 10.1371/journal.pone.0050787. Epub 2012 Dec 5. PLoS One. 2012. PMID: 23227209 Free PMC article. - Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus.
Huang J, Smirnov SV, Lewis-Antes A, Balan M, Li W, Tang S, Silke GV, Pütz MM, Smith GL, Kotenko SV. Huang J, et al. Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9822-7. doi: 10.1073/pnas.0610352104. Epub 2007 May 21. Proc Natl Acad Sci U S A. 2007. PMID: 17517620 Free PMC article. - Interferon-lambda as a potential therapeutic agent in cancer treatment.
Steen HC, Gamero AM. Steen HC, et al. J Interferon Cytokine Res. 2010 Aug;30(8):597-602. doi: 10.1089/jir.2010.0058. J Interferon Cytokine Res. 2010. PMID: 20645876 Free PMC article. Review. - IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity.
Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, Gamero AM. Maher SG, et al. Cancer Biol Ther. 2008 Jul;7(7):1109-15. doi: 10.4161/cbt.7.7.6192. Epub 2008 Apr 24. Cancer Biol Ther. 2008. PMID: 18698163 Free PMC article. - Interleukin 29 enhances expression of Toll receptor 3 and mediates antiviral signals in human keratinocytes.
Zhang SQ, Zhang Z, Luo X, Yang S, Chai Y, Huang HL, Yin XY, Hu DJ, Yang CJ, Liu JL, Zhang XJ. Zhang SQ, et al. Inflamm Res. 2011 Nov;60(11):1031-7. doi: 10.1007/s00011-011-0364-z. Epub 2011 Aug 17. Inflamm Res. 2011. PMID: 21847628
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous